Conventional Therapies Do Not Prolong the Prognosis of Hepatocellular Carcinoma Patients with Extrahepatic Metastases under Receiving of Tyrosine Kinase Inhibitors

SIMPLE SUMMARY: Tyrosine kinase inhibitors (TKIs), including sorafenib and lenvatinib, have been the current standard treatment for advanced hepatocellular carcinoma (HCC) in cases where an immune checkpoint inhibitor cannot be used. The SHARP study showed that sorafenib tended to be less effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Maeda, Hiroshi, Miura, Kouichi, Morimoto, Naoki, Watanabe, Shunji, Tsukui, Mamiko, Takaoka, Yoshinari, Nomoto, Hiroaki, Goka, Rie, Sato, Naoto, Morishima, Kazue, Sakuma, Yasunaru, Sata, Naohiro, Fukushima, Noriyoshi, Isoda, Norio, Yamamoto, Hironori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833467/
https://www.ncbi.nlm.nih.gov/pubmed/35159018
http://dx.doi.org/10.3390/cancers14030752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833467/
https://www.ncbi.nlm.nih.gov/pubmed/35159018
http://dx.doi.org/10.3390/cancers14030752

Ejemplares similares